Download the white paper to get an in-depth look into Aseptic Filling Workcells and Vanrx.
When a drug makes it to your filling line, the goal is to not mess it up. You try to remove risk as much as you can. That’s created a conservative environment where aseptic filling has followed
Is “gloveless isolator” the best term to describe a fully closed system for aseptic filling?
If you could reach GMP filling readiness two years early, what would it mean to your company's bottom line? The success of your product launches?
Filling personalized therapies? Here's the blueprint white paper.
These highly targeted therapies can have life-changing results, but the technologies needed to make them are lagging behind.
A column by Vanrx CEO Chris Procyshyn was featured in the March 2020 issue of The Medicine Maker. Chris discusses the importance of changing aseptic processing to include closed automated
How can filling technology help you produce in line with market demands? Reduce tech transfer times? By being agile in day-to-day operations and enabling scale out manufacturing models.
If you could reach GMP filling readiness two years early, what would it mean to your company's bottom line? The success of your product launches?
These highly targeted therapies can have life-changing results, but the technologies needed to make them are lagging behind.
The point we are making is that conventional filling machines are fundamentally flawed. But instead of solving these problems, new technologies are invented to bandage the flaws without solving
What's the common thread of all of the photos above? They are all the same machine. They are all highly flexible, capable of filling vials, syringes and cartridges. They all provide a closed